HEPA
- Hepion Pharmaceuticals, Inc.
()
Overview
Company Summary
Hepion Pharmaceuticals, Inc. (HEPA) is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for liver diseases. Specifically, HEPA focuses on the development of targeted therapeutic solutions for chronic liver diseases such as non-alcoholic steatohepatitis (NASH) and hepatitis virus infections.
NASH is a severe form of fatty liver disease, characterized by inflammation and liver cell damage. It can progress to more severe conditions such as cirrhosis, liver failure, and liver cancer. HEPA's primary focus is on its drug candidate CRV431, a cyclophilin inhibitor that has shown potential in reducing liver fibrosis and inflammation associated with NASH.
In addition to NASH, Hepion Pharmaceuticals is also exploring the application of its drug candidates for the treatment of hepatitis B and hepatitis D virus infections. These viral infections can lead to chronic liver damage, and there is a significant unmet need for effective treatment options.
HEPA utilizes advanced technologies, including computer modeling and screening, to identify drug candidates that have the potential to provide therapeutic benefits. With a strong emphasis on research and development, Hepion Pharmaceuticals aims to bring its innovative therapies to the market to address the growing concern of liver diseases, which currently lack effective treatments.
It is important to note that as a biopharmaceutical company, Hepion Pharmaceuticals does not operate clinical facilities or directly provide healthcare services. Instead, its focus lies in the research, development, and commercialization of potential therapies to improve patient outcomes and address the global burden of liver diseases.